Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood

Children and adolescents who present with neuroendocrine tumors are at extremely high likelihood of having an underlying germline predisposition for the multiple endocrine neoplasia (MEN) syndromes, including MEN1, MEN2A and MEN2B, MEN4, and hyperparathyroid-jaw tumor (HPT-JT) syndromes. Each of these autosomal dominant syndromes results from a specific germline mutation in unique genes: MEN1 is due to pathogenic MEN1 variants (11q13), MEN2A and MEN2B are due to pathogenic RET variants (10q11.21), MEN4 is due to pathogenic CDKN1B variants (12p13.1), and the HPT-JT syndrome is due to pathogenic CDC73 variants (1q25). Although each of these genetic syndromes share the presence of neuroendocrine tumors, each syndrome has a slightly different tumor spectrum with specific surveillance recommendations based upon tumor penetrance, including the age and location for which specific tumor types most commonly present. Although the recommended surveillance strategies for each syndrome contain similar approaches, important differences do exist among them. Therefore, it is important for caregivers of children and adolescents with these syndromes to become familiar with the unique diagnostic criteria for each syndrome, and also to be aware of the specific tumor screening and prophylactic surgery recommendations for each syndrome. Clin Cancer Res; 23(13); e123–e32. ©2017 AACR. See all articles in the online-only CCR Pediatric Oncology Series.

[1]  P. Chanson,et al.  From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. , 2017, Endocrine-related cancer.

[2]  J. Schiffman,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. , 2016, The Lancet. Oncology.

[3]  O. Dekkers,et al.  Impact of Delay in Diagnosis in Outcomes in MEN1: Results From the Dutch MEN1 Study Group. , 2016, The Journal of clinical endocrinology and metabolism.

[4]  Kathryn J. Rowland,et al.  Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2. , 2015, Annals of surgery.

[5]  Douglas B. Evans,et al.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. , 2015, Thyroid : official journal of the American Thyroid Association.

[6]  G. Cevenini,et al.  Reference range of serum calcitonin in pediatric population. , 2015, The Journal of clinical endocrinology and metabolism.

[7]  N. Perrier,et al.  CDC73-Related Disorders , 2015 .

[8]  P. Vestergaard,et al.  Aggressive medullary thyroid carcinoma in a ten-year-old patient with multiple endocrine neoplasia 2B due to the A883F mutation. , 2015, Thyroid.

[9]  E. Laws,et al.  Acromegaly: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[10]  Jeffrey E. Lee,et al.  Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. , 2014, Thyroid : official journal of the American Thyroid Association.

[11]  J. Varhaug,et al.  Surgical Curability of Medullary Thyroid Cancer in Multiple Endocrine Neoplasia 2B: A Changing Perspective , 2014, Annals of surgery.

[12]  A. Gill,et al.  Negative Parafibromin Staining Predicts Malignant Behavior in Atypical Parathyroid Adenomas , 2014, Annals of Surgical Oncology.

[13]  Tetsurou Yamamoto,et al.  Novel tandem germline RET proto‐oncogene mutations in a patient with multiple endocrine neoplasia type 2B: Report of a case and a literature review of tandem RET mutations with in silico analysis , 2013, Head & neck.

[14]  X. Hua,et al.  Menin: a scaffold protein that controls gene expression and cell signaling. , 2013, Trends in biochemical sciences.

[15]  N. Pellegata,et al.  Multiple endocrine neoplasia syndromes associated with mutation of p27 , 2013, Journal of Endocrinological Investigation.

[16]  T. Imai,et al.  High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. , 2013, European journal of endocrinology.

[17]  A. Tabarin,et al.  Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. , 2013, European journal of endocrinology.

[18]  S. Asa,et al.  Precursor lesions of endocrine system neoplasms , 2013, Pathology.

[19]  C. Stratakis,et al.  An update on the genetics of pheochromocytoma , 2013, Journal of Human Hypertension.

[20]  P. Chanson,et al.  Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. , 2013, The Journal of clinical endocrinology and metabolism.

[21]  J. Bilezikian,et al.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). , 2012, The Journal of clinical endocrinology and metabolism.

[22]  M. Bots,et al.  Predicting the risk of multiple endocrine neoplasia type 1 for patients with commonly occurring endocrine tumors. , 2012, European journal of endocrinology.

[23]  B. Estour,et al.  Cyclin-dependent kinase inhibitor 1B (CDKN1B) gene variants in AIP mutation-negative familial isolated pituitary adenoma kindreds. , 2012, Endocrine-related cancer.

[24]  N. Pellegata MENX and MEN4 , 2012, Clinics.

[25]  F. Raue,et al.  Genotype-phenotype correlation in multiple endocrine neoplasia type 2 , 2012, Clinics.

[26]  R. Lifton,et al.  Frequent Germ-Line Mutations of the MEN1, CASR, and HRPT2/CDC73 Genes in Young Patients with Clinically Non-familial Primary Hyperparathyroidism , 2012, Hormones and Cancer.

[27]  G. Viglietto,et al.  Functional characterization of a rare germline mutation in the gene encoding the cyclin-dependent kinase inhibitor p27Kip1 (CDKN1B) in a Spanish patient with multiple endocrine neoplasia-like phenotype. , 2012, European journal of endocrinology.

[28]  A. Manni,et al.  Familial hyperparathyroidism due to a germline mutation of the CDC73 gene: implications for management and age-appropriate testing of relatives at risk. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[29]  R. Thakker,et al.  Role of multiple endocrine neoplasia type 1 mutational analysis in clinical practice. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[30]  N. Pellegata,et al.  Somatic mutation and germline sequence abnormalities in CDKN1B, encoding p27Kip1, in sporadic parathyroid adenomas. , 2011, The Journal of clinical endocrinology and metabolism.

[31]  G. Cote,et al.  Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. , 2011, Thyroid : official journal of the American Thyroid Association.

[32]  Martin Fassnacht,et al.  Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10 , 2011, Human mutation.

[33]  N. Pellegata,et al.  A Novel Germline CDKN1B Mutation Causing Multiple Endocrine Tumors: Clinical, Genetic and Functional Characterization , 2010, Human mutation.

[34]  M. Georgitsi,et al.  MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations. , 2010, Best practice & research. Clinical endocrinology & metabolism.

[35]  R. Thakker,et al.  Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism‐jaw tumor syndrome (HPT‐JT) and parathyroid tumors , 2010, Human mutation.

[36]  A. Tabarin,et al.  Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients , 2010, World Journal of Surgery.

[37]  G. Palù,et al.  Hyperparathyroidism–jaw tumor syndrome: a report of three large kindred , 2009, Langenbeck's Archives of Surgery.

[38]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[39]  S. Marx,et al.  Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. , 2009, The Journal of clinical endocrinology and metabolism.

[40]  A. Tabarin,et al.  Thymic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1: A Comparative Study on 21 Cases Among a Series of 761 MEN1 from the GTE (Groupe des Tumeurs Endocrines) , 2009, World Journal of Surgery.

[41]  J. Bilezikian,et al.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. , 2009, The Journal of clinical endocrinology and metabolism.

[42]  L. Barzon,et al.  The extent of parathyroidectomy for HRPT2-related hyperparathyroidism. , 2009, Surgery.

[43]  S. Steinberg,et al.  The utility of routine transcervical thymectomy for multiple endocrine neoplasia 1-related hyperparathyroidism. , 2008, Surgery.

[44]  G. Palù,et al.  Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. , 2008, Endocrine-related cancer.

[45]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[46]  D. Figarella-Branger,et al.  Pituitary Tumors and Hyperplasia in Multiple Endocrine Neoplasia Type 1 Syndrome (MEN1): A Case-Control Study in a Series of 77 Patients Versus 2509 Non-MEN1 Patients , 2008, The American journal of surgical pathology.

[47]  R. Thakker,et al.  Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene , 2008, Human mutation.

[48]  Louise Izatt,et al.  Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. , 2007, The Journal of clinical endocrinology and metabolism.

[49]  R. DeLellis,et al.  Parafibromin in the Diagnosis of Parathyroid Carcinoma , 2007 .

[50]  C. Larsson,et al.  Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. , 2007, Endocrine-related cancer.

[51]  M. Tublin,et al.  Parathyroid imaging: technique and role in the preoperative evaluation of primary hyperparathyroidism. , 2007, AJR. American journal of roentgenology.

[52]  C. Marcocci,et al.  Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? , 2007, European journal of endocrinology.

[53]  H. Höfler,et al.  Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans , 2006, Proceedings of the National Academy of Sciences.

[54]  A. Gill,et al.  Loss of Nuclear Expression of Parafibromin Distinguishes Parathyroid Carcinomas and Hyperparathyroidism-Jaw Tumor (HPT-JT) Syndrome-related Adenomas From Sporadic Parathyroid Adenomas and Hyperplasias , 2006, The American journal of surgical pathology.

[55]  K. Owzar,et al.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. , 2005, The New England journal of medicine.

[56]  J. Carpten,et al.  Uterine tumours are a phenotypic manifestation of the hyperparathyroidism‐jaw tumour syndrome , 2005, Journal of internal medicine.

[57]  B. Teh,et al.  Renal neoplasia in the hyperparathyroidism-jaw tumor syndrome. , 2004, Current molecular medicine.

[58]  R. Jensen,et al.  Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. , 2004, The Journal of clinical endocrinology and metabolism.

[59]  E. Mallet,et al.  Reference intervals for serum calcitonin in men, women, and children. , 2004, Clinical chemistry.

[60]  Ximing J. Yang,et al.  Loss of Parafibromin Immunoreactivity Is a Distinguishing Feature of Parathyroid Carcinoma , 2004, Clinical Cancer Research.

[61]  H. Okinaga,et al.  RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan. , 2004, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[62]  A. Tanimoto,et al.  Ureteral leiomyoma causing hydronephrosis in Type 1 multiple endocrine neoplasia , 2004, Pathology international.

[63]  A. Vortmeyer,et al.  Meningiomas May Be a Component Tumor of Multiple Endocrine Neoplasia Type 1 , 2004, Clinical Cancer Research.

[64]  R. B. van der Luijt,et al.  Do patients with multiple endocrine neoplasia syndrome type 1 benefit from periodical screening? , 2003, European journal of endocrinology.

[65]  J. Carpten,et al.  HRPT2, encoding parafibromin, is mutated in hyperparathyroidism–jaw tumor syndrome , 2002, Nature Genetics.

[66]  S. Carty,et al.  Multiple endocrine neoplasia type 1: fresh perspective on clinical features and penetrance. , 2002, Surgical oncology.

[67]  T. Lairmore,et al.  Gastrointestinal Manifestations of Multiple Endocrine Neoplasia Type 2 , 2002, Annals of surgery.

[68]  G. Sassolas,et al.  Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. , 2002, Journal of Clinical Endocrinology and Metabolism.

[69]  B. Ponder,et al.  Guidelines for diagnosis and therapy of MEN type 1 and type 2. , 2001, The Journal of clinical endocrinology and metabolism.

[70]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[71]  M. Sawicki,et al.  Molecular and genetic mechanisms of tumorigenesis in multiple endocrine neoplasia type-1. , 2001, Molecular endocrinology.

[72]  R. Paschke,et al.  Familial isolated primary hyperparathyroidism--a multiple endocrine neoplasia type 1 variant? , 2001, European journal of endocrinology.

[73]  C. Scriver,et al.  The Metabolic and Molecular Bases of Inherited Disease, 8th Edition 2001 , 2001, Journal of Inherited Metabolic Disease.

[74]  I. Lubensky,et al.  Pituitary macroadenoma in a 5-year-old: an early expression of multiple endocrine neoplasia type 1. , 2000, The Journal of clinical endocrinology and metabolism.

[75]  W. Harmsen,et al.  Are Patients with Multiple Endocrine Neoplasia Type I Prone to Premature Death? , 2000, World Journal of Surgery.

[76]  M. Ichihara,et al.  A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations. , 2000, Biochemical and biophysical research communications.

[77]  R. Thakker,et al.  Multiple endocrine neoplasia type 1. , 1999, Endocrine-related cancer.

[78]  C. Eng,et al.  Intestinal ganglioneuromatosis and multiple endocrine neoplasia type 2B: implications for treatment , 1999, Gut.

[79]  A. Miyauchi,et al.  Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation , 1999, Japanese journal of cancer research : Gann.

[80]  J. Olson,et al.  Lethality of Multiple Endocrine Neoplasia Type I , 1998, World Journal of Surgery.

[81]  A. Vortmeyer,et al.  Multiple endocrine neoplasia 1 gene alterations in MEN1-associated and sporadic lipomas. , 1998, Journal of the National Cancer Institute.

[82]  P. Beck‐Peccoz,et al.  Multiple endocrine neoplasia type 1 in patients with recognized pituitary tumours of different types , 1997, Clinical endocrinology.

[83]  S. Steinberg,et al.  Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. , 1997, Archives of dermatology.

[84]  S. Egawa,et al.  A nationwide clinical survey of patients with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma in Japan. , 1997, Japanese journal of clinical oncology.

[85]  K. Herfarth,et al.  Surgical management of hyperparathyroidism in patients with multiple endocrine neoplasia type 2A. , 1996, Surgery.

[86]  C. Larsson,et al.  Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. , 1996, The Journal of clinical endocrinology and metabolism.

[87]  M. Endo,et al.  Multiple endocrine neoplasia type 1 associated with spinal ependymoma. , 1996, Internal medicine.

[88]  J. Rastad,et al.  Adrenal lesion in multiple endocrine neoplasia type 1. , 1995, Surgery.

[89]  B. Ponder,et al.  Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. , 1995, The Journal of clinical endocrinology and metabolism.

[90]  S. Chew,et al.  Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. , 1995, American journal of human genetics.

[91]  B. Ponder,et al.  Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma , 1995, Genes, chromosomes & cancer.

[92]  L. Mulligan,et al.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. , 1994, Human molecular genetics.

[93]  Elena S. Di Martino,et al.  Identification of the Cys634->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis , 1994, Journal of endocrinological investigation.

[94]  L. Bardram,et al.  Screening For Multiple Endocrine Neoplasia Type 1 In Patients With Recognized Pituitary Adenoma , 1990, Clinical endocrinology.

[95]  C. Larsson,et al.  Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma , 1988, Nature.

[96]  J. Sipple The association of pheochromocytoma with carcinoma of the thyroid gland , 1961 .

[97]  R. Fraser,et al.  Multiple Endocrine Adenomas , 1960 .

[98]  C. Jackson Hereditary hyperparathyroidism associated with recurrent pancreatitis. , 1958, Annals of internal medicine.

[99]  P. Wermer Genetic aspects of adenomatosis of endocrine glands. , 1954, The American journal of medicine.

[100]  F. Raue,et al.  [Multiple endocrine neoplasia]. , 2017, Deutsche medizinische Wochenschrift.

[101]  S. Wajner,et al.  Advances and controversies in the management of medullary thyroid carcinoma , 2017, Current opinion in oncology.

[102]  E. Capoluongo,et al.  Multiple endocrine neoplasia type 1 (MEN1): An update of 208 new germline variants reported in the last nine years. , 2016, Cancer genetics.

[103]  P. Chanson,et al.  Genetic mutations in sporadic pituitary adenomas—what to screen for? , 2015, Nature Reviews Endocrinology.

[104]  T. Bacchella,et al.  Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life. , 2014, The Journal of clinical endocrinology and metabolism.

[105]  Douglas B. Evans,et al.  Ultrasonography Should Not Guide the Timing of Thyroidectomy in Pediatric Patients Diagnosed with Multiple Endocrine Neoplasia Syndrome 2A through Genetic Screening , 2012, Annals of Surgical Oncology.

[106]  M. Iacobone,et al.  Hyperparathyroidism-Jaw Tumor Syndrome , 2020, Definitions.

[107]  R. DeLellis Pathology and genetics of tumours of endocrine organs , 2004 .

[108]  G M Lenoir,et al.  Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. , 1997, American journal of human genetics.

[109]  C. Eng,et al.  Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma [4] , 1997 .

[110]  J. Higginson,et al.  International Agency for Research on Cancer. , 1968, WHO chronicle.

[111]  B. M. Black,et al.  Multiple endocrine adenomas; report of 8 cases in which the parathyroids, pituitary and pancreatic islets were involved. , 1953, The Journal of clinical endocrinology and metabolism.